Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295102> ?p ?o ?g. }
- W4286295102 endingPage "9507" @default.
- W4286295102 startingPage "9507" @default.
- W4286295102 abstract "9507 Background: Cancer is a leading cause of death among KTR, but these patients (pts) have been excluded from trials of immune checkpoint inhibitors due to immunosuppression and risk of allograft loss. We report findings from the first prospective clinical trial of NIVO + TACRO + PRED +/- IPI in KTR with selected advanced cutaneous cancers. Methods: The primary composite endpoint was lack of tumor progression per RECIST v1.1 without allograft loss at 16 weeks (W) on NIVO. Adult KTR with advanced melanoma, basal, cutaneous squamous, or Merkel cell carcinoma (MEL, BCC, CSCC, MCC), for whom non-immune therapies were insufficient were eligible. Immunosuppression was standardized to low-dose TACRO (goal trough 2-5 ng/mL) + PRED 5mg daily; pts then received NIVO 480mg IV q4W. Pts with progressive disease (PD) could receive NIVO 3mg/kg + IPI 1mg/kg IV q3W x 4 followed by NIVO 480mg IV q4W. Donor-derived cell-free DNA (dd-cfDNA) levels were measured q2W as a potential predictor of allograft rejection. Results: From 11/2019 - 4/2021, of 12 pts enrolled, 8 pts with CSCC, MCC or MEL were evaluable for response (Table). All pts experienced PD on NIVO; treatment-related allograft loss (TRAL) occurred in 1 pt. 6 pts then received IPI + NIVO. Responses: 2 (33%) with marked tumor regression at 6W and eventual complete response (CR; 1 with TRAL), and 4 (67%) with PD (1 with TRAL). 7/8 pre-NIVO tumor biopsies contained a paucity of infiltrating immune cells. Only 2/5 on-NIVO biopsies demonstrated moderate immune infiltrates; both of these pts later developed a CR to IPI + NIVO. Rejecting allografts contained dense immune responses (plasma cells, CD4+ & CD8+ lymphocytes, PD-1+ lymphocytes, macrophages, PD-L1+ glomerular endothelium, and focal PD-1 & PD-L1 positivity in renal tubules). In 2/3 pts with TRAL, elevations in dd-cfDNA levels occurred 10 and 15 days earlier than increases in weekly serum creatinine levels. TRAL #3 occurred after discontinuation of study therapy (including TACRO) and dd-cfDNA monitoring. Conclusions: In KTR receiving low-dose TACRO + PRED, NIVO augments tumor immune cell infiltration in some pts but is insufficient to mediate tumor regression. Adding IPI can enhance anti-tumor immunity and mediate tumor regression. TACRO + PRED was insufficient to prevent allograft rejection after PD-1 +/- CTLA-4 blockade in 2/8 pts. In pts with TRAL, increased dd-cfDNA levels preceded increased serum creatinine. Based on these findings, we are modifying the trial therapy regimen to augment anti-tumor immunity and preserve allograft function. Clinical trial information: NCT03816332. [Table: see text]" @default.
- W4286295102 created "2022-07-21" @default.
- W4286295102 creator A5001082049 @default.
- W4286295102 creator A5009470957 @default.
- W4286295102 creator A5012274871 @default.
- W4286295102 creator A5014494747 @default.
- W4286295102 creator A5022594161 @default.
- W4286295102 creator A5030169825 @default.
- W4286295102 creator A5035471137 @default.
- W4286295102 creator A5035539932 @default.
- W4286295102 creator A5040976474 @default.
- W4286295102 creator A5041066193 @default.
- W4286295102 creator A5052980036 @default.
- W4286295102 creator A5058902095 @default.
- W4286295102 creator A5060456478 @default.
- W4286295102 creator A5063337705 @default.
- W4286295102 creator A5074261196 @default.
- W4286295102 creator A5075566772 @default.
- W4286295102 creator A5079599604 @default.
- W4286295102 creator A5088644322 @default.
- W4286295102 date "2022-06-01" @default.
- W4286295102 modified "2023-10-18" @default.
- W4286295102 title "Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers." @default.
- W4286295102 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.9507" @default.
- W4286295102 hasPublicationYear "2022" @default.
- W4286295102 type Work @default.
- W4286295102 citedByCount "5" @default.
- W4286295102 countsByYear W42862951022022 @default.
- W4286295102 countsByYear W42862951022023 @default.
- W4286295102 crossrefType "journal-article" @default.
- W4286295102 hasAuthorship W4286295102A5001082049 @default.
- W4286295102 hasAuthorship W4286295102A5009470957 @default.
- W4286295102 hasAuthorship W4286295102A5012274871 @default.
- W4286295102 hasAuthorship W4286295102A5014494747 @default.
- W4286295102 hasAuthorship W4286295102A5022594161 @default.
- W4286295102 hasAuthorship W4286295102A5030169825 @default.
- W4286295102 hasAuthorship W4286295102A5035471137 @default.
- W4286295102 hasAuthorship W4286295102A5035539932 @default.
- W4286295102 hasAuthorship W4286295102A5040976474 @default.
- W4286295102 hasAuthorship W4286295102A5041066193 @default.
- W4286295102 hasAuthorship W4286295102A5052980036 @default.
- W4286295102 hasAuthorship W4286295102A5058902095 @default.
- W4286295102 hasAuthorship W4286295102A5060456478 @default.
- W4286295102 hasAuthorship W4286295102A5063337705 @default.
- W4286295102 hasAuthorship W4286295102A5074261196 @default.
- W4286295102 hasAuthorship W4286295102A5075566772 @default.
- W4286295102 hasAuthorship W4286295102A5079599604 @default.
- W4286295102 hasAuthorship W4286295102A5088644322 @default.
- W4286295102 hasConcept C121608353 @default.
- W4286295102 hasConcept C126322002 @default.
- W4286295102 hasConcept C143998085 @default.
- W4286295102 hasConcept C203092338 @default.
- W4286295102 hasConcept C2777546739 @default.
- W4286295102 hasConcept C2777701055 @default.
- W4286295102 hasConcept C2778342957 @default.
- W4286295102 hasConcept C2778720950 @default.
- W4286295102 hasConcept C2780030458 @default.
- W4286295102 hasConcept C2780252810 @default.
- W4286295102 hasConcept C2781433595 @default.
- W4286295102 hasConcept C2909675724 @default.
- W4286295102 hasConcept C2911091166 @default.
- W4286295102 hasConcept C535046627 @default.
- W4286295102 hasConcept C71924100 @default.
- W4286295102 hasConcept C90924648 @default.
- W4286295102 hasConceptScore W4286295102C121608353 @default.
- W4286295102 hasConceptScore W4286295102C126322002 @default.
- W4286295102 hasConceptScore W4286295102C143998085 @default.
- W4286295102 hasConceptScore W4286295102C203092338 @default.
- W4286295102 hasConceptScore W4286295102C2777546739 @default.
- W4286295102 hasConceptScore W4286295102C2777701055 @default.
- W4286295102 hasConceptScore W4286295102C2778342957 @default.
- W4286295102 hasConceptScore W4286295102C2778720950 @default.
- W4286295102 hasConceptScore W4286295102C2780030458 @default.
- W4286295102 hasConceptScore W4286295102C2780252810 @default.
- W4286295102 hasConceptScore W4286295102C2781433595 @default.
- W4286295102 hasConceptScore W4286295102C2909675724 @default.
- W4286295102 hasConceptScore W4286295102C2911091166 @default.
- W4286295102 hasConceptScore W4286295102C535046627 @default.
- W4286295102 hasConceptScore W4286295102C71924100 @default.
- W4286295102 hasConceptScore W4286295102C90924648 @default.
- W4286295102 hasFunder F4320332161 @default.
- W4286295102 hasIssue "16_suppl" @default.
- W4286295102 hasLocation W42862951021 @default.
- W4286295102 hasOpenAccess W4286295102 @default.
- W4286295102 hasPrimaryLocation W42862951021 @default.
- W4286295102 hasRelatedWork W2320598948 @default.
- W4286295102 hasRelatedWork W2885885878 @default.
- W4286295102 hasRelatedWork W2936810997 @default.
- W4286295102 hasRelatedWork W2947988614 @default.
- W4286295102 hasRelatedWork W3084353392 @default.
- W4286295102 hasRelatedWork W3099471488 @default.
- W4286295102 hasRelatedWork W3210028029 @default.
- W4286295102 hasRelatedWork W4211002949 @default.
- W4286295102 hasRelatedWork W4308384320 @default.
- W4286295102 hasRelatedWork W2964438262 @default.
- W4286295102 hasVolume "40" @default.
- W4286295102 isParatext "false" @default.
- W4286295102 isRetracted "false" @default.